The potential role of positron emission mammography for detection of breast cancer. A phantom study

2000 ◽  
Vol 27 (8) ◽  
pp. 1943-1954 ◽  
Author(s):  
Raymond R. Raylman ◽  
Stan Majewski ◽  
Randy Wojcik ◽  
Andrew G. Weisenberger ◽  
Brian Kross ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Potential Role ◽  
Phantom Study ◽  
Positron Emission Mammography ◽  
Positron Emission

Positron emission mammography in the diagnosis of breast cancer

2016 ◽  
Vol 55 (01) ◽  
pp. 15-20 ◽  
Author(s):  
J. Farahati ◽  
A. G. Müller ◽  
E. Gillman ◽  
M. Hentschel ◽  
F. H. H. Müller
Keyword(s):  
Breast Cancer ◽  
High Specificity ◽  
Diagnostic Value ◽  
Glandular Tissue ◽  
Breast Cancer Patients ◽  
Malignant Tumours ◽  
Benign Lesions ◽  
Interventional Study ◽  
Positron Emission Mammography ◽  
Positron Emission

SummaryAim: To evaluate the diagnostic value (sensitivity, specificity) of positron emission mammography (PEM) in a single site non-interventional study using the maximum PEM uptake value (PUVmax). Patients, methods: In a singlesite, non-interventional study, 108 patients (107 women, 1 man) with a total of 151 suspected lesions were scanned with a PEM Flex Solo II (Naviscan) at 90 min p.i. with 3.5 MBq 18F-FDG per kg of body weight. In this ROI(region of interest)-based analysis, maximum PEM uptake value (PUV) was determined in lesions, tumours (PUVmaxtumour), benign lesions (PUVmaxnormal breast) and also in healthy tissues on the contralateral side (PUVmaxcontralateral breast). These values were compared and contrasted. In addition, the ratios of PUVmaxtumour / PUVmaxcontralateral breast and PUVmaxnormal breast / PUVmaxcontralateral breast were compared. The image data were interpreted independently by two experienced nuclear medicine physicians and compared with histology in cases of suspected carcinoma. Results: Based on a criteria of PUV>1.9, 31 out of 151 lesions in the patient cohort were found to be malignant (21%). A mean PUVmaxtumour of 3.78 ± 2.47 was identified in malignant tumours, while a mean PUVmaxnormal breast of 1.17 ± 0.37 was reported in the glandular tissue of the healthy breast, with the difference being statistically significant (p < 0.001). Similarly, the mean ratio between tumour and healthy glandular tissue in breast cancer patients (3.15 ± 1.58) was found to be significantly higher than the ratio for benign lesions (1.17 ± 0.41, p < 0.001). Conclusion: PEM is capable of differentiating breast tumours from benign lesions with 100% sensitivity along with a high specificity of 96%, when a threshold of PUVmax >1.9 is applied.

The potential role of ERβ isoforms in the clinical management of breast cancer

2008 ◽  
Vol 53 (4) ◽  
pp. 374-380 ◽  
Author(s):  
C A Green ◽  
M B Peter ◽  
V Speirs ◽  
A M Shaaban
Keyword(s):  
Breast Cancer ◽  
Clinical Management ◽  
Potential Role

scholarly journals The potential role of cofilin-1 in promoting triple negative breast cancer (TNBC) metastasis via the extracellular vesicles (EVs)

2022 ◽  
Vol 15 (1) ◽  
pp. 101247
Author(s):  
Jane Howard ◽  
Chia Yin Goh ◽  
Karolina Weiner Gorzel ◽  
Michaela Higgins ◽  
Amanda McCann
Keyword(s):  
Breast Cancer ◽  
Extracellular Vesicles ◽  
Triple Negative Breast Cancer ◽  
Potential Role ◽  
Triple Negative

Identification of non-invasive biomarkers for early detection of breast cancer: A Review

2021 ◽  
Vol 2 (1) ◽  
pp. 01-05
Author(s):  
Asima Tayyab
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Potential Role ◽  
Small Volume ◽  
Breast Cancer Diagnosis ◽  
Diagnostic Purpose ◽  
Diagnose Breast Cancer ◽  
Non Invasive ◽  
Early Stages

Despite decades of research, diagnostic tests with specificity and accuracy for early breast cancer are yet unavailable. Major problems associated with poor diagnosis are either due to incompetency of reported biomarkers or small volume of patients under study. Moreover, heterogeneity of the disease further complicates the struggle of identifying effective biomarkers. Therefore, to improve the survival rate, look for new, sensitive and specific biomarkers for early breast cancer diagnosis is need of hour. In this study, we have reviewed recently reported serum biomarkers and categorized them based on their biomolecular nature such as protein, ctDNA, epigenetics regulation and miRNA. Potential role of these available biomarkers in early diagnosis of breast cancer has also been discussed. Based on the facts obtained from literature review, it is revealed that using any individual biomolecule as a biomarker is not sufficient to diagnose breast cancer at early stages rather it is suggested that a panel of proteins or miRNAs would offer better sensitivity and specificity. Whereas, unavailability of a potential ctDNA and epigenetics regulation candidate for diagnostic purpose is and suggest the use of more sophisticated techniques to unwound these regulations in serum especially at early stages of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document